Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€20.56

€20.56

-6.550%
-1.44
-6.550%
-
 
17:26 / Tradegate WKN: A2AFL6 / Name: Syndax / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Syndax

sharewise wants to provide you with the best news and tools for Syndax, so we directly link to the best financial data sources.

News

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset: https://cdn.content.foolcdn.com/images/1umn9qeh/production/d227e0f40b399dc519a5bed98ee8a4568fc6efb8-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset

DAFNA Capital Management reported selling 222,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.89 million based on

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish: https://cdn.content.foolcdn.com/images/1umn9qeh/production/0fe050b5d35dffd742b195c313bda291f30dfea0-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment: https://cdn.content.foolcdn.com/images/1umn9qeh/production/c1631655103f7157a9e8d36ebaec7d6a2cfb7675-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment

On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $6.54 million trade based on quarterly average